Breaking News: EGPA Treatment Approved

December 14, 2017

GlaxoSmithKline has announced that the FDA has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.

Read the Announcement